GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poniard Pharmaceuticals Inc (OTCPK:PARD) » Definitions » Piotroski F-Score

Poniard Pharmaceuticals (Poniard Pharmaceuticals) Piotroski F-Score : 0 (As of May. 29, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Poniard Pharmaceuticals Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Poniard Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Poniard Pharmaceuticals's Piotroski F-Score or its related term are showing as below:


Poniard Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for Poniard Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poniard Pharmaceuticals Piotroski F-Score Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 4.00 2.00 2.00 3.00

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 3.00 - - -

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep11) TTM:Last Year (Sep10) TTM:
Net Income was -5.167 + -3.246 + -3.858 + -3.771 = $-16.04 Mil.
Cash Flow from Operations was -5.046 + -2.021 + -1.682 + -1.708 = $-10.46 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Sep10)
to the end of this year (Sep11) was
(31.144 + 11.643 + 12.219 + 9.989 + 7.736) / 5 = $14.5462 Mil.
Total Assets at the begining of this year (Sep10) was $31.14 Mil.
Long-Term Debt & Capital Lease Obligation was $1.64 Mil.
Total Current Assets was $2.25 Mil.
Total Current Liabilities was $2.98 Mil.
Net Income was -13.168 + -11.889 + -6.546 + -6.449 = $-38.05 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Sep09)
to the end of last year (Sep10) was
(49.64 + 52.442 + 46.979 + 37.282 + 31.144) / 5 = $43.4974 Mil.
Total Assets at the begining of last year (Sep09) was $49.64 Mil.
Long-Term Debt & Capital Lease Obligation was $6.59 Mil.
Total Current Assets was $24.36 Mil.
Total Current Liabilities was $12.43 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Poniard Pharmaceuticals's current Net Income (TTM) was -16.04. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Poniard Pharmaceuticals's current Cash Flow from Operations (TTM) was -10.46. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep10)
=-16.042/31.144
=-0.51509119

ROA (Last Year)=Net Income/Total Assets (Sep09)
=-38.052/49.64
=-0.76655923

Poniard Pharmaceuticals's return on assets of this year was -0.51509119. Poniard Pharmaceuticals's return on assets of last year was -0.76655923. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Poniard Pharmaceuticals's current Net Income (TTM) was -16.04. Poniard Pharmaceuticals's current Cash Flow from Operations (TTM) was -10.46. ==> -10.46 > -16.04 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep11)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep10 to Sep11
=1.64/14.5462
=0.11274422

Gearing (Last Year: Sep10)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep09 to Sep10
=6.585/43.4974
=0.15138836

Poniard Pharmaceuticals's gearing of this year was 0.11274422. Poniard Pharmaceuticals's gearing of last year was 0.15138836. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep11)=Total Current Assets/Total Current Liabilities
=2.252/2.979
=0.75595838

Current Ratio (Last Year: Sep10)=Total Current Assets/Total Current Liabilities
=24.358/12.425
=1.96040241

Poniard Pharmaceuticals's current ratio of this year was 0.75595838. Poniard Pharmaceuticals's current ratio of last year was 1.96040241. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Poniard Pharmaceuticals's number of shares in issue this year was 1.498. Poniard Pharmaceuticals's number of shares in issue last year was 1.206. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Poniard Pharmaceuticals's gross margin of this year was . Poniard Pharmaceuticals's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep10)
=0/31.144
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep09)
=0/49.64
=0

Poniard Pharmaceuticals's asset turnover of this year was 0. Poniard Pharmaceuticals's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Poniard Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Poniard Pharmaceuticals  (OTCPK:PARD) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Poniard Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Poniard Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Poniard Pharmaceuticals (Poniard Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.
Executives
Michael S Perry officer: President & CMO C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Ron Martell director, officer: Chief Executive Officer PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
David R Stevens director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Gerald Phd Mcmahon director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Carl Goldfischer director 161 WEST 61ST STREET, NEW YORK NY 10022
Fred B Craves director 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Simon Nicholas J Iii director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Gregory L Weaver officer: Chief Financial Officer 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Kurt Wheeler 10 percent owner 801 GATEWAY BLVD, STE 410, SAN FRANCISCO CA 94080
Mpm Asset Management Investors 2005 Bviii Llc 10 percent owner C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE 31ST FLOOR, BOSTON MA 02199
Nicholas Galakatos 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Dennis Henner 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Michael Steinmetz 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Luke Evnin 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116

Poniard Pharmaceuticals (Poniard Pharmaceuticals) Headlines